Oura Ring Gen 4 sensor data — not clinical measurementsN=1 case study — not validated for clinical decisionsHEV diagnosed Mar 18; interpret findings cautiously in this Day 66 post-ruxolitinib window

Weekly Tracker

2026-05-16 to 2026-05-22

Generated 2026-05-22 07:22 · Patient 1 — Weekly Tracker

GREEN

On Track

Metrics in normal range

AMBER

Watch

Borderline or declining

RED

Alert

Needs attention

IMPROVING

Normal

Week-over-week

DECLINING

Critical

Week-over-week

Doctor Summary — Week of 2026-05-16 to 2026-05-22

ATTENTION: REM Sleep is declining at 0.9 h (-19.2% week-over-week)
ATTENTION: Temp Deviation is declining at 0.29 °C (+216.4% week-over-week)
Steps improved +379.6% to 7221 steps
Recovery Index improved +45.5% to 82 pts
Readiness Score declined -9.3% to 73 pts -- monitor

Metric Details

HRV (RMSSD)

28.8ms

↑ +10.1%Last week: 26.2 ms

Lowest HR

55.8bpm

↓ -6.5%Last week: 59.7 bpm

Average HR

68.9bpm

↔ -1.3%Last week: 69.8 bpm

Sleep Duration

6.5h

↔ -1.8%Last week: 6.7 h

Deep Sleep

1.0h

↓ -7.6%Last week: 1.1 h

REM Sleep

0.9h

↓ -19.2%Last week: 1.1 h

Sleep Efficiency

82%

↓ -5.3%Last week: 86 %

Readiness Score

73pts

↓ -9.3%Last week: 80 pts

Recovery Index

82pts

↑ +45.5%Last week: 56 pts

Steps

7221steps

↑ +379.6%Last week: 1506 steps

Temp Deviation

0.29°C

↓ +216.4%Last week: 0.09 °C

Breath Rate

14.1brpm

↓ -10.1%Last week: 15.7 brpm

Ruxolitinib Progress

Day 67 on ruxolitinib (started 2026-03-16)

Metric	Pre-Rux Baseline	This Week	Change
HRV (RMSSD)	11.7 ms	28.8 ms	↑ +145.9%
Lowest HR	73.0 bpm	55.8 bpm	↓ -23.6%
Average HR	80.5 bpm	68.9 bpm	↓ -14.4%
Sleep Duration	6.0 h	6.5 h	↑ +9.4%
Deep Sleep	1.0 h	1.0 h	↑ +1.9%
REM Sleep	0.8 h	0.9 h	↑ +2.6%
Sleep Efficiency	79 %	82 %	↑ +3.3%
Readiness Score	69 pts	73 pts	↑ +4.8%
Recovery Index	63 pts	82 pts	↑ +30.6%
Steps	2540 steps	7221 steps	↑ +184.2%
Temp Deviation	0.21 °C	0.29 °C	↑ +41.0%
Breath Rate	14.0 brpm	14.1 brpm	↑ +1.2%

All metrics derived from Oura Ring Gen 4 consumer wearable data. Not clinical-grade measurements.

Single-patient case study (N=1). Not validated for clinical decision-making. Not a medical device.

Data: January 08 – May 20, 2026 · Post-intervention: 66 days (ruxolitinib, March 16)